

INDUSTRY COUNCIL

2027 Sponsorship Prospectus

About the Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Founded in 2006 in Salt Lake City, Utah, by a family who lost a loved one to the disease, CCF has grown into a global leader in patient support, education, advocacy, and funding basic, clinical, and translational research. CCF's core values are patients first, collaboration, innovation, and urgency.

About our Industry Council Membership

Launched in 2019, the Cholangiocarcinoma Foundation's Industry Council brings together testing companies, pharmaceutical and biotechnology partners committed to advancing research, education, awareness, and support for the cholangiocarcinoma community.

Through curated engagement with CCF leadership, patients, caregivers, clinicians, researchers, and advocates, Industry Council members gain meaningful insight into the evolving CCA landscape, emerging community needs, barriers to care, clinical trial challenges, and opportunities to strengthen patient-centered collaboration.

The Council currently includes six member companies and provides a collaborative forum to prioritize key topics, share ideas, strengthen cross-sector engagement, and identify opportunities for partnership in areas of mutual interest.

Industry Council membership is designed to foster strategic partnership, support transparent dialogue, and create opportunities for companies to better understand and serve the CCA community.

"The Cholangiocarcinoma Foundation Industry Council offers a unique opportunity to engage in meaningful conversations with those who deeply understand patient needs and challenges. These exchanges help us be more thoughtful partners in bringing new medicines to patients."

— AstraZeneca

2027 Membership Details

The annual Industry Council membership fee is **\$40,000**. Membership is valid annually from **January through December**.

To ensure members receive the full range of benefits, recognition, and engagement opportunities, CCF kindly requests that membership pledges be submitted by **February 1, 2027**. We recognize that internal approval timelines vary and are happy to work with your organization should additional flexibility be needed.

Why Become A Member

Industry Council membership provides companies with a unique opportunity to engage directly with the CCA community while gaining strategic insight from CCF leadership and key stakeholders across the field.

Membership is especially valuable for company representatives working in:

- | | | | |
|------------------------|----------------------------|--------------------------------|--|
| • Patient Advocacy | • Health Equity and Access | • Research and Development | • Corporate Social Responsibility |
| • Medical Affairs | | • Commercial Strategy | • Grants, Sponsorships, and Strategic Partnerships |
| • Clinical Development | • Corporate Affairs | • Marketing and Communications | |
| • Clinical Operations | • External Engagement | | |

For companies developing therapies, supporting clinical trials, launching educational initiatives, or seeking to better understand the needs of patients and caregivers, the Industry Council offers a focused forum for connection, learning, and collaboration.

For more information, contact:

Kaylin Allenbrand, Director of Corporate Partnerships, kaylin.allenbrand@curecca.org

2027 Industry Council Membership Benefits

1. In-Person Patient Roundtable at the CCF Annual Conference

Industry Council members are invited to an exclusive, in-person patient roundtable during the CCF Annual Conference. This CCF-moderated discussion brings together industry partners, patients, and caregivers to explore key topics including research, drug development, clinical trial access, patient education, support resources, and unmet needs.

The roundtable provides a unique opportunity to hear directly from the CCA community while participating in thoughtful discussions that help inform the future of patient care.

Benefits include:

- Participation in a CCF-moderated discussion with patients and caregivers
- Direct insight into patient experiences, priorities, and barriers to care
- Dialogue on treatment development, clinical trials, access, and patient support
- Logo on the Patient Roundtable digital invitation
- Logo on Patient Roundtable welcome slide

2. Annual Industry Update Webinar Presentation

Industry Council membership includes one presentation during CCF's Annual Industry Update Webinar, conducted post-ASCO in July of each year.

This patient-focused educational program allows companies to share clinical trial updates, emerging data, treatment information, and highlights from major oncology meetings with patients, caregivers, healthcare professionals, and the broader CCA community.

Each participating company receives approximately 10 minutes to present in clear, accessible language.

In 2026, the inaugural webinar attracted 200 registrants, 113 live attendees, and more than 350 YouTube views within two weeks, demonstrating strong community interest in timely updates from industry leaders.

Benefits include:

- One presentation during the Annual Industry Update Webinar

- Approximately 10 minutes of presentation time
- Opportunity to share clinical trial updates, research findings, treatment information, or conference highlights

Note: Non-Industry Council companies may participate for a separate fee of \$10,000, pending availability.

Optional consideration: If two Industry Update Webinars are offered in 2027, Industry Council members would receive one included presentation plus priority access or a discounted rate for the second webinar.

3. End-of-Year State of the Foundation Briefing

Industry Council members are invited to an exclusive virtual briefing with CCF executive leadership. This annual session provides a strategic overview of CCF's accomplishments, community insights, organizational priorities, and goals for the coming year, along with an opportunity for member questions and feedback.

Topics include:

- Year-in-review highlights and impact
- Updates on the evolving cholangiocarcinoma landscape
- CCF priorities in research, education, advocacy, access, and patient support
- Patient and caregiver insights
- Emerging opportunities for collaboration
- Moderated Q&A with executive leadership

4. Recognition on the CCF Website

Listed as an official Industry Council member on the CCF website, recognizing your organization's commitment to advancing cholangiocarcinoma research, education, advocacy, and patient support.

5. Premium Exhibit Booth Placement at the Annual Conference

Receive priority booth placement in the conference exhibit hall, providing prominent visibility in a high-traffic location near general sessions and meal functions.

Since joining the Cholangiocarcinoma Foundation's Industry Council, Compass Therapeutics has truly valued the opportunity to be part of such thoughtful and patient-focused conversations. We have enjoyed engaging with CCF and fellow drug developers who share a common goal of advancing care and bringing more treatment options to people living with cholangiocarcinoma. The collaboration, openness, and shared commitment across the Council have made our participation especially meaningful. Partnering with CCF has been a wonderful experience, and we are grateful for the relationship we have built and for all they do to support patients, caregivers, and the broader cholangiocarcinoma community.

- Compass Therapeutics

Thank you to our 2026 Industry Council Members



CCF's obligation is fulfilled by delivering on the commitments articulated in this prospectus for the year or years indicated above, as well as by the value the sponsor receives from its association with CCF's intellectual capital, partners, and constituents.